

WATSON PHARMACEUTICALS INC  
 Form 4  
 September 17, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 CHAO ALLEN

(Last) (First) (Middle)

C/O WATSON  
 PHARMACEUTICALS, INC., 311  
 BONNIE CIRCLE

(Street)

CORONA, CA 92880

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 WATSON PHARMACEUTICALS  
 INC [WPI]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/13/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Executive Chairman

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	(1) (2) (3) (4) (5) (6) (7) (8)
Common Stock, par value \$0.0033	09/13/2007		S		50,000	D	712,875 D
Common Stock, par value \$0.0033	09/14/2007		S		50,000	D	662,875 D
Common Stock, par							883,468 I by Trust

value  
\$0.0033

Common Stock, par value \$0.0033 959,083 I by Corporation

Common Stock, par value \$0.0033 09/13/2007 S 60,000 D (9) 1,358,661 I by Partnership

Common Stock, par value \$0.0033 09/14/2007 S 40,000 D (10) 1,318,661 I by Partnership

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V (A) (D)		

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CHAO ALLEN C/O WATSON PHARMACEUTICALS, INC. 311 BONNIE CIRCLE CORONA, CA 92880	X		Executive Chairman	



Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

@\$31; 100 @\$31; 200 @\$31; 100 @\$31; 300 @\$31; 100 @\$31; 100 @\$31.01; 300 @\$31.01; 800 @\$31; 600 @\$31; 100 @\$31; 100 @\$31; 400 @\$31; 400 @\$31; 300 @\$31; 100 @\$31; 400 @\$31; 100 @\$31.02; 300 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.02; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 300 @\$31.02; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 200 @\$31.01

continued: 100@\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 200 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 200 @\$31; 100 @\$31; 100 @\$31; 200 @\$31; 76 @\$31; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.04; 100 @\$31.05; 100 @\$31.05; 100 @\$31.05; 100 @\$31.05; 300 @\$31.06; 100 @\$31.02; 200 @\$31.03; 100 @\$31.02; 100 @\$31.02; 300 @\$31.02; 100 @\$31; 100 @\$31; 100 @\$31.01; 100 @\$31; 100 @\$31.01; 600 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 300 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31; 100 @\$31; 100 @\$31; 200 @\$31; 100 @\$31.01; 100 @\$31.01; 200 @\$31.01; 100 @\$31; 100 @\$31; 200 @\$31; 400 @\$31.01; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.04; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 200 @\$31; 300 @\$31.03; 100 @\$31.01; 400 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31; 100 @\$31.01

(7) continued: 200 @\$31.01; 100 @\$31.01; 100 @\$31.03; 300 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.03; 100 @\$31.02; 300 @\$31.02; 100 @\$31.03; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.02; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01; 100 @\$31.01

(8) The shares were sold at the following prices: 2,200 @\$30.88; 1,700 @\$30.9; 100 @\$30.91; 2,700 @\$30.92; 400 @\$30.93; 900 @\$30.95; 200 @\$30.96; 500 @\$30.98; 100 @\$30.99; 400 @\$31.04; 500 @\$31.08; 300 @\$31.09; 1,328 @\$31.1; 1,172 @\$31.11; 200 @\$31.115; 700 @\$31.12; 400 @\$31.14; 2,984 @\$31.15; 2,016 @\$31.16; 1,000 @\$31.165; 900 @\$31.17; 300 @\$31.175; 2,900 @\$31.18; 2,400 @\$31.19; 600 @\$31.195; 800 @\$31.2; 300 @\$31.21; 1,800 @\$31.22; 100 @\$31.225; 1,800 @\$31.23; 700 @\$31.235; 1,900 @\$31.24; 400 @\$31.245; 100 @\$31.25; 300 @\$31.27; 100 @\$31.275; 100 @\$31.28; 100 @\$31.285; 500 @\$31.31; 300 @\$31.315; 800 @\$31.32; 300 @\$31.325; 2,600 @\$31.33; 400 @\$31.335; 6,200 @\$31.34; 300 @\$31.345; 3,600 @\$31.35; 300 @\$31.355; 1,200 @\$31.36; 200 @\$31.37; 700 @\$31.38; 100 @\$31.385; 500 @\$31.39; 1,300 @\$31.4; 200 @\$31.405; 500 @\$31.41; 500 @\$31.42; 600 @\$31.43; 100 @\$31.435; 300 @\$31.45; 100 @\$31.455; 600 @\$31.46; 300 @\$31.47; 200 @\$31.475; 700 @\$31.48; 200 @\$31.485; 200 @\$31.49; 700 @\$31.5; and 100 @\$31.51

(9) The shares were sold at the following prices: 1,400 @\$31.02; 15,100 @\$31; 400 @\$31.005; 100 @\$31.025; 100 @\$31.035; 2,500 @\$31.03; 7,800 @\$31.01; 300 @\$31.22; 600 @\$31.2; 1,000 @\$31.21; 400 @\$31.15; 800 @\$31.13; 700 @\$31.14; 600 @\$31.12; 1,700 @\$31.19; 1,100 @\$31.16; 100 @\$31.25; 600 @\$31.24; 900 @\$31.3; 200 @\$31.26; 900 @\$31.23; 2,100 @\$31.17; 600 @\$31.18

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.